Try our Advanced Search for more refined results
Life Sciences
-
November 30, 2023
FDA Promotes Chief Scientist To Deputy Commissioner
After less than two years as the U.S. Food and Drug Administration's chief scientist, Namandjé N. Bumpus, a pharmacology Ph.D. who specializes in HIV research, has been selected as the agency's next principal deputy commissioner.
-
November 30, 2023
11th Circ. Orders New Trial In Pill Mill Row Over Ruan
The Eleventh Circuit gave a new trial to a Florida doctor accused of participating in a pill mill scheme after finding that the district court's jury instructions failed to properly instruct whether the doctor acted with criminal intent after new mens rea precedent in USA v. Ruan.
-
November 30, 2023
Justices Told PTAB's Ax Of Ventilator Patent Was Wrong Call
A California State University, Fullerton, professor has asked the U.S. Supreme Court to review a Federal Circuit decision that refused to revive claims in her patent on a medical ventilator, challenging the circuit court's finding that the claims were obvious.
-
November 30, 2023
Republican AGs Assail Abortion Coverage Law At 9th Circ.
Almost two dozen red states and various religious freedom groups told the Ninth Circuit that a lower court ruling in favor of a Washington law requiring employee health plans to cover abortion services tramples over religious rights.
-
November 30, 2023
Wachtell Lipton Guiding AbbVie On $10.1B ImmunoGen Buy
AbbVie Inc. said Thursday it has agreed to buy cancer drugmaker ImmunoGen Inc. at a total equity value of approximately $10.1 billion, with representation from Wachtell Lipton Rosen & Katz, sending the stock soaring 80% in pre-market trading Thursday.
-
November 29, 2023
Fed. Circ. Told To Defer To ITC In Apple Watch IP Row
A small Silicon Valley medical device startup's efforts to use the U.S. International Trade Commission to litigate allegations that Apple Inc. pilfered health tracking software for its smartwatches have drawn supportive amicus briefs from a handful of trade groups, a billionaire venture capitalist and a Japanese manufacturer of health monitors.
-
November 29, 2023
House Told AI Is A Tool, Not A Decision Maker, In Health Care
Amid expanding innovations in artificial intelligence in the health care industry, from AI scribes of patient visits to algorithm-driven medical imaging, experts are urging lawmakers to develop regulation and oversight to avoid compromising patient safety and privacy.
-
November 29, 2023
Investors Say Co. Lied About Ultrasound Tech Prior To Merger
A pair of shareholders in digital health company Butterfly Network Inc. have launched a derivative suit against the company's current and former top brass, alleging they drastically inflated the company's sales projections and the quality of its main ultrasound product to convince investors to approve a merger with a special-purpose acquisition company.
-
November 29, 2023
Eli Lilly Partners With Prism BioLab In Deal Worth $660M
Pharmaceutical company Eli Lilly and Japanese biotech company Prism BioLab are partnering in a deal worth up to $660 million to discover and develop a new protein-protein interaction target, Prism said Tuesday.
-
November 29, 2023
New York Electric Utility Escapes Insurer's $3.7M Lab Fire Suit
A New York federal judge allowed an electric utility to escape a Zurich unit's subrogation suit over $3.7 million in coverage for a laboratory fire, ruling Wednesday that the insurer failed to prove the company caused the 2018 blaze.
-
November 29, 2023
Pharma Co. Says 'Ulterior' Aim Shouldn't Kill Records Suit
A clinical-stage biopharma company that failed to force a potential acquisition target to open its corporate books said Wednesday that Delaware's Court of Chancery "misapplied governing law" by denying the inspection, and urged Delaware's Supreme Court to reverse the decision.
-
November 29, 2023
Drug Giants Face 3rd RICO Suit In 3 Weeks Over Insulin Prices
A Maryland county south of Washington, D.C., has joined the flood of litigation accusing drugmakers and pharmacy benefit managers of violating a federal racketeering law in a scheme to jack up insulin prices.
-
November 29, 2023
How New Expert-Witness Rules Put Science Front And Center
New rules taking effect Friday are set to revamp how courts accept or reject expert witnesses, with a focus on the science underpinning their opinions. Law360 spoke to a lawyer whose article helped spur the changes.
-
November 29, 2023
AbbVie Tells 3rd Circ. 'Sham' Case Ruling 'Explodes' Privilege
Judges on a Third Circuit panel were skeptical Wednesday of arguments from AbbVie Inc. that a lower court's ruling on discovery of attorney communications in a "sham" patent case would open the floodgates to privilege challenges any time a drug company files a suit that slows down a competitor.
-
November 28, 2023
Insurers Escape Allergy Treatment Groups' Antitrust Claims
A Louisiana federal court has tossed antitrust claims from allergy testing and immunotherapy outfits against Blue Cross Blue Shield of Louisiana and other insurers after finding a lack of evidence showing a conspiracy to push the groups out of the market.
-
November 28, 2023
Biotech Co.'s Counterclaims Against Ex-Exec Trimmed
A California federal judge has tossed a Colorado biotechnology company's counterclaims alleging fraud and negligent misrepresentation by a co-founder and technology chief of another firm it acquired for $35 million in 2022, but allowed the biotech's bid for declaratory relief regarding the executive's exit from the company to move forward.
-
November 28, 2023
UCLA Study Finds Calif. Teens Can't Get Plan B At Pharmacies
Pharmacies in California are denying adolescents emergency contraception like Plan B despite a state law giving minors access to that treatment, according to a new study released by a research center at the UCLA School of Law.
-
November 28, 2023
Drugmakers Argue Double Patenting Ruling Defies Congress
AbbVie, Merck, Johnson & Johnson, AstraZeneca, Novartis and other big-name pharmaceutical companies are urging the full Federal Circuit to reconsider a patent invalidation that they say placed a judicially made rule above law set by Congress.
-
November 28, 2023
Group Says Doctor COVID-19 Disinformation Suit Isn't Moot
The New Civil Liberties Alliance has told a California federal court that a suit over a California law punishing medical professionals for COVID-19 disinformation should move forward despite a newly enacted law repealing it because doctors still suffered damages and the state is sidestepping a potentially adverse ruling.
-
November 28, 2023
Mich. Health Dept. Asks 6th Circ. To Back Baby Blood Program
Michigan health officials urged the Sixth Circuit Monday to reverse a ruling that dismantled its newborn blood-screening program, calling that program a "paragon of good government."
-
November 28, 2023
Daiichi Awarded $46M Fees In Cancer Drug Patent Arbitration
Japanese drugmaker Daiichi Sankyo Ltd. has scored nearly $46 million in fees and costs in an arbitration initiated by rival Seagen in the companies' patent dispute over cancer drug technology after the arbitrator found that the U.S. biotech company did not file its infringement claims within the six-year statute of limitations.
-
November 28, 2023
Sanctioned Wholesaler Wants Abbott Labs Out Of Her Trust
A medical wholesaler executive's wife is trying to stop Abbott Laboratories from reaching into her trust in order to satisfy a $33 million judgment against the pair that came after they were found to have engaged in discovery fraud.
-
November 28, 2023
Rep. Eshoo On Retiring: 'Health Care Has Been My North Star'
Over three decades on Capitol Hill and five presidential administrations, Rep. Anna G. Eshoo has left a deep mark on American health care and the pharmaceutical industry. As she prepares to retire, the California Democrat spoke with Law360 about what sparked her interest in health care reform, the battle to pass the Affordable Care Act and what she hasn't been able to accomplish in her long career.
-
November 28, 2023
USPTO Wants Antibody Patent Case Sent Back For Review
The U.S. Patent and Trademark Office says the Federal Circuit should terminate Xencor Inc.'s appeal of a Patent Trial and Appeal Board decision that backed an examiner's denial of an application for a patent on antibodies that can be used in autoimmune disease treatments.
-
November 28, 2023
Fajr Capital-Led Consortium Paying $1B For Aster's Gulf Biz
An Allen & Overy-advised consortium led by Dubai-based Fajr Capital has agreed to acquire 65% of hospital chain Aster DM Healthcare's Gulf Cooperation Council business for $1 billion, Fajr said Tuesday.
Expert Analysis
-
Tips For Litigating Against Pro Se Parties In Complex Disputes
Litigating against self-represented parties in complex cases can pose unique challenges for attorneys, but for the most part, it requires the same skills that are useful in other cases — from documenting everything to understanding one’s ethical duties, says Bryan Ketroser at Alto Litigation.
-
What Pharma Cos. Must Know About FDA Off-Label Guidance
The U.S. Food and Drug Administration recently issued draft guidance on how pharmaceutical companies should share research on off-label use of medical devices, outlining how firms could avoid enforcement action — especially when disseminating self-created content about their own products, say Jacqueline Berman and Maarika Kimbrell at Morgan Lewis.
-
It's Time To Prescribe Frameworks For AI-Driven Health Care
As health care providers begin to adopt artificial intelligence in clinical settings, new legal and regulatory challenges are emerging, with the critical issue being balancing AI's benefits and innovations in health care while ensuring patient safety and provider accountability, say attorneys at Kirkland.
-
The Murky World Of IP Protection For Gene-Edited Plants
The recently filed Corteva v. Inari lawsuit, which accuses a plant trait developer of using a front company for commercial development, underscores the legal challenges in protecting and determining the ownership of new, genetically edited plant varieties, and emphasizes why joint development arrangements must be carefully navigated, say Andrew Zappia and Tate Tischner at Troutman Pepper.
-
New Initiatives Will Advance Corporate Biodiversity Reporting
Two important recent developments — the launch of the Taskforce on Nature-related Financial Disclosures' framework on nature and biodiversity reporting, and Nature Action 100's announcement of the 100 companies it plans to engage on biodiversity issues — will help bring biodiversity disclosures into the mainstream, say David Woodcock and Maria Banda at Gibson Dunn.
-
Opinion
Alternative Patents Would Solve Many Inventor Woes
A fundamental reform that gives inventors the option of alternative patents tailored to the value of an invention offers a potential solution for resolving patent-system problems, says John Powers of The Powers IP Law Firm.
-
Class Action Defense: Don't Give Up On Bristol-Myers Squibb
Federal appellate court decisions in the six years since the U.S. Supreme Court decided Bristol-Myers Squibb show that it's anyone's ballgame in class action jurisdictional arguments, so defendants are encouraged to consider carefully whether, where and when arguing lack of specific personal jurisdiction may be advantageous, say attorneys at K&L Gates.
-
Pro Bono Work Is Powerful Self-Help For Attorneys
Oct. 22-28 is Pro Bono Week, serving as a useful reminder that offering free legal help to the public can help attorneys expand their legal toolbox, forge community relationships and create human connections, despite the challenges of this kind of work, says Orlando Lopez at Culhane Meadows.
-
FDA Proposals Clarify Rules For Devices With Predicates
As medical devices continue to grow in complexity, U.S. Food and Drug Administration policies surrounding premarket submissions for devices with existing predicates have fallen behind, but new draft guidances from the agency help fill in some gaps, say attorneys at Hogan Lovells.
-
State Regs Sow Discord Between Cannabis, Hemp Industries
Connecticut, Maryland and Washington are the latest states choosing to require intoxicating hemp products to comply with the states' recreational marijuana laws, resulting in a widening rift between cannabis and hemp as Congress works on crafting new hemp legislation within the upcoming 2023 Farm Bill, say attorneys at Wilson Elser.
-
Series
Playing In A Rock Cover Band Makes Me A Better Lawyer
Performing in a classic rock cover band has driven me to hone several skills — including focus, organization and networking — that have benefited my professional development, demonstrating that taking time to follow your muse outside of work can be a boon to your career, says Michael Gambro at Cadwalader.
-
AI May Help Patent Applicants With Functional Claiming
The U.S. Supreme Court recently set what many patent practitioners consider too high a bar for functional claims, but artificial intelligence could alter functionality analysis — conferring predictability that alleviates courts' concerns that practicing the claims requires undue experimentation, say Brian Nolan and Ying-Zi Yang at Mayer Brown.
-
How Int'l Regulatory Collabs Can Expedite Pharma Approvals
Recent announcements highlight the growing importance of international regulatory collaboration for drug approval, which can greatly streamline the process for companies seeking to market their drugs in other countries, say Geneviève Michaux and Christina Markus at King & Spalding.
-
How Executives' Deposition Standards Can Differ
The recent Trustees of Purdue University v. Wolfspeed Inc. decision granting a motion on a protective order for a high-level witness shows how courts can vary in the application of the apex doctrine and analysis under Rule 26 of the Federal Rule of Civil Procedure, say Genevieve Halpenny and John Cook at Barclay Damon.
-
Series
The Pop Culture Docket: Judge Espinosa On 'Lincoln Lawyer'
The murder trials in Netflix’s “The Lincoln Lawyer” illustrate the stark contrast between the ethical high ground that fosters and maintains the criminal justice system's integrity, and the ethical abyss that can undermine it, with an important reminder for all legal practitioners, say Judge Adam Espinosa and Andrew Howard at the Colorado 2nd Judicial District Court.